23-Jul-2020 - Evotec SE

Evotec to produce monoclonal antibody products against COVID-19 for the Department of Defense

Contract valued up to $ 18.2 m

Evotec SE announced that the U.S. Department of Defense (“DOD”) awarded its Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to $ 18.2 m to develop and manufacture monoclonal antibodies (“mAbs”) for treatment and/or prevention of COVID-19. The goal of this programme is to rapidly and efficiently deliver the mAbs to the DOD.

The DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (“JPEO-CBRND”) is executing this effort in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (“OASD(HA)”) and the Defense Health Agency (“DHA”).

Under the contract, Just – Evotec Biologics will design a highly efficient manufacturing process for the production of Current Good Manufacturing Practice (“cGMP”) clinical supplies of two monoclonal antibodies directed against SARS-CoV-2 antigens. The mAbs will be tested in early-stage clinical trials and ultimately, used for intervention and/or prevention of SARS-CoV-2 infections. Just – Evotec Biologics will use its extensive experience in process development and clinical manufacturing to enable the rapid realisation of these potentially critical protein therapeutic treatments against SARS CoV 2 infections.

Dr James Thomas, Executive Vice President Global Head Biotherapeutics at Just – Evotec Biologics commented: “It is an honour to be working with the Department of Defense on this important and time-critical programme. The response to COVID-19 requires the application of rapid, flexible, scalable and robust development and manufacturing technologies. Our company and our platform were designed for the type of rapid response required to develop safe and efficacious products needed for the fight against COVID-19 and future pandemics.”

Dr Craig Johnstone, Chief Operating Officer of Evotec, added: “Evotec is committed to the global fight against COVID-19 and future pandemic preparedness. We are very pleased to be one of the service providers to the U.S. Department of Defense and to apply our expertise and advanced technologies to respond rapidly to this significant global health crisis.”

Facts, background information, dossiers
  • Covid-19
  • SARS-CoV-2
More about Evotec
  • News

    Evotec and Novo Nordisk form alliance to develop novel therapies for kidney diseases

    Evotec SE and Novo Nordisk announced a strategic collaboration on the discovery and development of innovative therapeutics for patients with chronic kidney disease. Evotec and Novo Nordisk will jointly identify and develop novel targets based on comprehensive medical and molecular data sets ... more

    Evotec and Secarna form strategic partnership in the field of antisense therapy

    Evotec SE and Secarna Pharmaceuticals GmbH & Co. KG (Secarna) announced a strategic partnership in the field of antisense oligonucleotide (“ASO”)-based therapeutics. Antisense therapy is an innovative, clinically and commercially validated, highly-targeted pharmacological approach which int ... more

    Evotec enters partnership with Vienna start-up

    Evotec SE announced that the Company has entered into a comprehensive partnership with the recently established QUANTRO Therapeutics GmbH, a research-based biotech company based in Vienna, Austria, that strives to discover and develop novel therapeutics interfering with disease-causing tran ... more

  • Companies

    Evotec SE

    Evotec is a leading drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches. The Company operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target ... more

    Evotec Neurosciences GmbH

    Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is b ... more

More about U.S. Department of Defense